Case report: coeliac disease as a cause of secondary failure of glibenclamide therapy in a patient with permanent neonatal diabetes due to KCNJ11/R201C mutation

Diabetologia. 2021 Jul;64(7):1703-1706. doi: 10.1007/s00125-021-05454-y. Epub 2021 May 14.

Affiliations

¹ Department of Pediatrics, University of Campania 'Luigi Vanvitelli', Naples, Italy. dario.iafusco@unicampania.it.
² Department of Pediatrics, University of Campania 'Luigi Vanvitelli', Naples, Italy.
³ Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.

No abstract available

Keywords: Coeliac disease; Glibenclamide therapy; KCNJ11 mutation; Permanent neonatal diabetes; Secondary failure.

Publication types

Case Reports
Letter

MeSH terms

Amino Acid Substitution
Arginine / genetics
Celiac Disease / complications*
Celiac Disease / diet therapy
Celiac Disease / drug therapy
Child, Preschool
Combined Modality Therapy
Cysteine / genetics
Diabetes Mellitus / diet therapy
Diabetes Mellitus / drug therapy*
Diabetes Mellitus / genetics
Diet, Gluten-Free
Female
Glyburide / therapeutic use*
Humans
Italy
Mutation, Missense
Potassium Channels, Inwardly Rectifying / genetics
Treatment Failure

Substances

Kir6.2 channel
Potassium Channels, Inwardly Rectifying
Arginine
Cysteine
Glyburide

Supplementary concepts

Diabetes Mellitus, Permanent Neonatal